Senores Pharma Q1 FY27: No deviation in preferential warrant fund usage
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals filed a statement confirming no deviation in use of funds raised via preferential issue of 11,70,000 convertible equity warrants at Rs 812 each, totaling about Rs 95 crore raised on March 28, 2026. In Q1 FY27 (quarter ended June 30, 2026), the company used about Rs 16.91 crore for working capital (Rs 6.84 cr), subsidiary loans (Rs 6.15 cr), and general corporate purposes (Rs 3.92 cr). No funds used yet for product development. Audit Committee reviewed and Board took it on record.
Confirms proper use of raised funds with no deviations. Product development allocation of Rs 25 cr remains untouched, which investors may monitor for delays.